UniProt ID | CENPR_HUMAN | |
---|---|---|
UniProt AC | Q13352 | |
Protein Name | Centromere protein R | |
Gene Name | ITGB3BP | |
Organism | Homo sapiens (Human). | |
Sequence Length | 177 | |
Subcellular Localization |
Isoform 1: Nucleus. Chromosome, centromere. Chromosome, centromere, kinetochore. Isoform 2: Nucleus. Isoform 3: Nucleus. Cytoplasm. Isoform 3 is predominantly nuclear and weakly cytoplasmic. Isoform 4: Cytoplasm. |
|
Protein Description | Transcription coregulator that can have both coactivator and corepressor functions. Isoform 1, but not other isoforms, is involved in the coactivation of nuclear receptors for retinoid X (RXRs) and thyroid hormone (TRs) in a ligand-dependent fashion. In contrast, it does not coactivate nuclear receptors for retinoic acid, vitamin D, progesterone receptor, nor glucocorticoid. Acts as a coactivator for estrogen receptor alpha. Acts as a transcriptional corepressor via its interaction with the NFKB1 NF-kappa-B subunit, possibly by interfering with the transactivation domain of NFKB1. Induces apoptosis in breast cancer cells, but not in other cancer cells, via a caspase-2 mediated pathway that involves mitochondrial membrane permeabilization but does not require other caspases. May also act as an inhibitor of cyclin A-associated kinase. Also acts a component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex.. | |
Protein Sequence | MPVKRSLKLDGLLEENSFDPSKITRKKSVITYSPTTGTCQMSLFASPTSSEEQKHRNGLSNEKRKKLNHPSLTESKESTTKDNDEFMMLLSKVEKLSEEIMEIMQNLSSIQALEGSRELENLIGISCASHFLKREMQKTKELMTKVNKQKLFEKSTGLPHKASRHLDSYEFLKAILN | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
6 | Phosphorylation | --MPVKRSLKLDGLL --CCCCCCCCCCCHH | 24.92 | 21712546 | |
8 | Sumoylation | MPVKRSLKLDGLLEE CCCCCCCCCCCHHCC | 45.86 | - | |
8 | Ubiquitination | MPVKRSLKLDGLLEE CCCCCCCCCCCHHCC | 45.86 | - | |
8 | Sumoylation | MPVKRSLKLDGLLEE CCCCCCCCCCCHHCC | 45.86 | 28112733 | |
17 | Phosphorylation | DGLLEENSFDPSKIT CCHHCCCCCCHHHCC | 34.01 | 25159151 | |
18 (in isoform 5) | Phosphorylation | - | 27.82 | 24719451 | |
18 | Phosphorylation | GLLEENSFDPSKITR CHHCCCCCCHHHCCC | 27.82 | 24719451 | |
21 | Phosphorylation | EENSFDPSKITRKKS CCCCCCHHHCCCCCE | 38.24 | 26074081 | |
22 | Sumoylation | ENSFDPSKITRKKSV CCCCCHHHCCCCCEE | 54.18 | 28112733 | |
22 | Ubiquitination | ENSFDPSKITRKKSV CCCCCHHHCCCCCEE | 54.18 | - | |
27 | Methylation | PSKITRKKSVITYSP HHHCCCCCEEEEECC | 46.82 | - | |
28 | Phosphorylation | SKITRKKSVITYSPT HHCCCCCEEEEECCC | 23.06 | 30266825 | |
31 | Phosphorylation | TRKKSVITYSPTTGT CCCCEEEEECCCCCE | 18.78 | 30266825 | |
32 | Phosphorylation | RKKSVITYSPTTGTC CCCEEEEECCCCCEE | 11.09 | 30266825 | |
33 | Phosphorylation | KKSVITYSPTTGTCQ CCEEEEECCCCCEEE | 13.71 | 30266825 | |
35 | Phosphorylation | SVITYSPTTGTCQMS EEEEECCCCCEEEEE | 31.73 | 30266825 | |
36 | Phosphorylation | VITYSPTTGTCQMSL EEEECCCCCEEEEEE | 33.60 | 30266825 | |
38 | Phosphorylation | TYSPTTGTCQMSLFA EECCCCCEEEEEEEE | 9.47 | 30266825 | |
42 | Phosphorylation | TTGTCQMSLFASPTS CCCEEEEEEEECCCC | 8.41 | 30266825 | |
46 | Phosphorylation | CQMSLFASPTSSEEQ EEEEEEECCCCHHHH | 22.75 | 30266825 | |
48 | Phosphorylation | MSLFASPTSSEEQKH EEEEECCCCHHHHHH | 42.25 | 30266825 | |
49 | Phosphorylation | SLFASPTSSEEQKHR EEEECCCCHHHHHHH | 38.85 | 30266825 | |
50 | Phosphorylation | LFASPTSSEEQKHRN EEECCCCHHHHHHHC | 47.86 | 30266825 | |
56 | Phosphorylation | SSEEQKHRNGLSNEK CHHHHHHHCCCCHHH | 46.04 | 27251275 | |
60 | Phosphorylation | QKHRNGLSNEKRKKL HHHHCCCCHHHHHHC | 44.32 | 20860994 | |
66 | Sumoylation | LSNEKRKKLNHPSLT CCHHHHHHCCCCCCC | 59.56 | - | |
66 | Ubiquitination | LSNEKRKKLNHPSLT CCHHHHHHCCCCCCC | 59.56 | - | |
66 | Sumoylation | LSNEKRKKLNHPSLT CCHHHHHHCCCCCCC | 59.56 | - | |
71 | Phosphorylation | RKKLNHPSLTESKES HHHCCCCCCCCCCCC | 40.13 | 10490654 | |
72 | Phosphorylation | KKLNHPSLTESKEST HHCCCCCCCCCCCCC | 7.89 | 24719451 | |
73 | Phosphorylation | KLNHPSLTESKESTT HCCCCCCCCCCCCCC | 42.42 | 28450419 | |
74 | Phosphorylation | LNHPSLTESKESTTK CCCCCCCCCCCCCCC | 66.17 | 27251275 | |
75 | Phosphorylation | NHPSLTESKESTTKD CCCCCCCCCCCCCCC | 36.17 | 23186163 | |
76 | Ubiquitination | HPSLTESKESTTKDN CCCCCCCCCCCCCCH | 49.83 | - | |
81 | Ubiquitination | ESKESTTKDNDEFMM CCCCCCCCCHHHHHH | 55.40 | - | |
92 | Sumoylation | EFMMLLSKVEKLSEE HHHHHHHHHHHHHHH | 55.15 | - | |
92 | Ubiquitination | EFMMLLSKVEKLSEE HHHHHHHHHHHHHHH | 55.15 | - | |
92 | Sumoylation | EFMMLLSKVEKLSEE HHHHHHHHHHHHHHH | 55.15 | - | |
126 | Phosphorylation | LENLIGISCASHFLK HHHHHHHHHHHHHHH | 9.83 | 20068231 | |
129 | Phosphorylation | LIGISCASHFLKREM HHHHHHHHHHHHHHH | 21.06 | 20068231 | |
133 | Ubiquitination | SCASHFLKREMQKTK HHHHHHHHHHHHHHH | 45.42 | - | |
154 | Ubiquitination | NKQKLFEKSTGLPHK HHHHHHHHHHCCCCH | 46.08 | - | |
155 | Phosphorylation | KQKLFEKSTGLPHKA HHHHHHHHHCCCCHH | 22.10 | 27251275 | |
156 | Phosphorylation | QKLFEKSTGLPHKAS HHHHHHHHCCCCHHH | 54.53 | 27251275 | |
161 | Ubiquitination | KSTGLPHKASRHLDS HHHCCCCHHHHCCCH | 46.23 | - | |
163 | Phosphorylation | TGLPHKASRHLDSYE HCCCCHHHHCCCHHH | 25.65 | 27251275 | |
168 | Phosphorylation | KASRHLDSYEFLKAI HHHHCCCHHHHHHHH | 32.68 | 20068231 | |
169 | Phosphorylation | ASRHLDSYEFLKAIL HHHCCCHHHHHHHHH | 15.46 | 29496907 | |
172 (in isoform 5) | Ubiquitination | - | 2.15 | - | |
173 | Ubiquitination | LDSYEFLKAILN--- CCHHHHHHHHHC--- | 38.41 | - | |
195 | Phosphorylation | ------------------------- ------------------------- | 27251275 | ||
207 | Phosphorylation | ------------------------------------- ------------------------------------- | 27251275 | ||
208 | Phosphorylation | -------------------------------------- -------------------------------------- | 27251275 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
28 | S | Phosphorylation | Kinase | PAK1 | Q13153 | PSP |
33 | S | Phosphorylation | Kinase | CDK2 | P24941 | PSP |
46 | S | Phosphorylation | Kinase | CDK2 | P24941 | PSP |
- | K | Ubiquitination | E3 ubiquitin ligase | TRAF6 | Q9Y4K3 | PMID:16252010 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CENPR_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CENPR_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND MASSSPECTROMETRY. |